13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

10 trials found

diseases per page:

Showing 1 to 10 of 10 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-000048-23-DE (EUCTR)	03/03/2022	07/10/2021	Study to test IMU-838 in patients with progressive multiple sclerosis	Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and To ...	Progressive forms of Multiple Sclerosis MedDRA version: 21.1;Level: PT;Classification code 10053395; ...	Product Name: IMU-838 INN or Proposed INN: Vidofludimus calcium Other descriptive name: IM90838 Product ...	Immunic AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	450	Phase 2	United States;Serbia;Czechia;Finland;Ukraine;North Macedonia;Russian Federation;Hungary;Canada;Polan ...
2	EUCTR2021-000048-23-NL (EUCTR)	10/02/2022	12/10/2021	Study to test IMU-838 in patients with progressive multiple sclerosis	Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and To ...	Progressive forms of Multiple Sclerosis MedDRA version: 21.1;Level: PT;Classification code 10053395; ...	Product Name: IMU-838 INN or Proposed INN: Vidofludimus calcium Other descriptive name: IM90838 Product ...	Immunic AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	450	Phase 2	Serbia;United States;Czechia;Finland;Ukraine;North Macedonia;Russian Federation;Hungary;Canada;Polan ...
3	EUCTR2021-000028-36-BG (EUCTR)	18/01/2022	08/11/2021	Not applicable	A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Toler ...	Relapsing Multiple Sclerosis MedDRA version: 21.0;Level: PT;Classification code 10080700;Term: Relap ...	Product Name: vidofludimus calcium Product Code: IMU-838 INN or Proposed INN: Vidofludimus calcium Othe ...	Immunic AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	1050	Phase 3	United States;Belarus;Greece;Ukraine;Lithuania;North Macedonia;Russian Federation;Colombia;India;Mex ...
4	EUCTR2021-000048-23-BG (EUCTR)	28/10/2021	28/09/2021	Study to test IMU-838 in patients with progressive multiple sclerosis	Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and To ...	Progressive forms of Multiple Sclerosis MedDRA version: 21.1;Level: PT;Classification code 10053395; ...	Product Name: IMU-838 INN or Proposed INN: Vidofludimus calcium Other descriptive name: IM90838 Product ...	Immunic AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	450	Phase 2	Serbia;Czechia;Finland;Ukraine;North Macedonia;Russian Federation;Hungary;Poland;Romania;Bulgaria;Ge ...
5	EUCTR2018-001896-19-BG (EUCTR)	17/12/2018	11/10/2018	Randomized, double-blind, placebo-controlled, multicenter Phase 2 trial assessing the effect of IMU- ...	Randomized, double-blind, placebo-controlled, multicenter Phase 2 trial assessing the effect of IMU- ...	relapsing-remitting multiple sclerosis MedDRA version: 21.1;Level: PT;Classification code 10063399;T ...	Product Name: VIDOFLUDIMUS CALCIUM Product Code: IMU-838 INN or Proposed INN: Vidofludimus calcium Prod ...	Immunic AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	195	Phase 2	Poland;Ukraine;Romania;Bulgaria
6	NCT02636829 (ClinicalTrials.gov)	March 2016	17/11/2015	Validation of Self-administered Questionnaire for Assessing CalciumIntake in Patients With Multiple ...	Validation of Self-administered Questionnaire Specifically for Assessing CalciumIntake (QALCIMUM®) i ...	Multiple Sclerosis;Rheumatoid Arthritis	Other: QALCIMUM questionnaire;Other: Determination of calcium intake by a dietician interview	Centre Hospitalier Universitaire de Nimes	NULL	Completed	18 Years	69 Years	Both	100	N/A	France
7	NCT01166178 (ClinicalTrials.gov)	October 2010	19/7/2010	Zoledronic Acid in MS-patients With Osteoporosis	A 1-year, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluat ...	Osteoporosis;Multiple Sclerosis	Drug: Zoledronic Acid;Drug: Placebo;Dietary Supplement: Calcium and Vitamin D combination	Novartis	NULL	Terminated	18 Years	75 Years	All	29	Phase 3	Germany
8	NCT00785473 (ClinicalTrials.gov)	January 2008	4/11/2008	Can Vitamin D Supplementation Prevent Bone Loss in Persons With Multiple Sclerosis	Can Vitamin D Supplementation Prevent Bone Loss in Persons With MS? A Randomised, Placebo-controlled ...	Multiple Sclerosis, Osteoporosis	Dietary Supplement: cholecalciferol;Dietary Supplement: calcium carbonate	University Hospital of North Norway	NULL	Completed	18 Years	50 Years	Both	80	Phase 4	Norway
9	NCT00644904 (ClinicalTrials.gov)	July 2006	24/3/2008	Safety Trial of High Dose Oral Vitamin D3 With Calcium in Multiple Sclerosis	A Phase I/II Dose-Escalation Trial of Vitamin D3 With CalciumSupplementation in Patients With Multip ...	Multiple Sclerosis	Dietary Supplement: Vitamin D3	University of Toronto	Direct MS-Proactive Charity;Multiple Sclerosis Society of Canada	Completed	18 Years	55 Years	Both	49	Phase 1/Phase 2	Canada
10	EUCTR2005-006071-12-IT (EUCTR)	31/08/2005	09/05/2006	Evaluation of efficacy, safety and tolerability of an ADd-on therapy with Cianocabalamine Vitamin B1 ...	Evaluation of efficacy, safety and tolerability of an ADd-on therapy with Cianocabalamine Vitamin B1 ...	MULTIPLE SCLEROSIS MedDRA version: 6.1;Level: PT;Classification code 10028245	Trade Name: EPARMEFOLIN 30 CPR 0,1/0,5MG INN or Proposed INN: CALCIOFOLINATO DC.IT INN or Proposed INN ...	AZIENDA OSPEDALIERA SAN CAMILLO FORLANINI	NULL	Not Recruiting			Female: yes Male: yes	276		Italy

First Previous1Next Last